New research suggests menopause is associated with brain volume loss in key regions tied to memory and emotions, along with higher rates of anxiety, depression, and sleep issues.
Hormone therapy didn’t prevent these changes, though it may slow age-related declines in reaction speed.
Menopause linked to brain changes and mental health challenges.
Dr. Natalie Yivgi-Ohana, Ph.D. — CEO, Minovia Therapeutics — Harnessing The Therapeutic Power Of Mitochondria
Is Co-Founder and CEO of Minovia Therapeutics (https://minoviatx.com/), a biotech company dedicated to rapidly advance life-changing therapies that address the unmet need of serious and complex mitochondrial diseases, and are the first clinical-stage company to develop a mitochondrial transplantation approach to treat a broad range of indications generated by a mitochondrial dysfunction which lead to rare-genetic or age-related diseases.
Dr. Yivgi-Ohana has twenty years of experience in mitochondrial research and received her Ph.D. in Biochemistry at The Hebrew University, after which she completed her postdoctoral fellowship at the Weizmann Institute of Science.
Dr. Yivgi-Ohana also has her B.Sc., Medical Sciences Ben-Gurion University of the Negev and her Master’s Degree, Human Reproduction Bar-Ilan University.
Dr. Yivgi-Ohana founded Minovia with a passion to help children and adults with mitochondrial diseases worldwide.
University of Queensland researchers say the discovery of a new stress reduction role for a naturally occurring molecule in the body could lead to new drugs and treatment for metabolic disorders and aging.
Professor Steven Zuryn, a molecular geneticist from UQ’s Queensland Brain Institute, was part of a team that found that very small RNA molecules, called microRNAs, bind to genes and prevent them from being over-activated.
MicroRNAs were discovered in C. elegans about 30 years ago and have since been shown to be important in human health and disease. This initial discovery led to the 2024 Nobel Prize in Physiology or Medicine.
Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD
Discount Links/Affiliates:
Blood testing (where I get the majority of my labs): https://www.ultalabtests.com/partners/michaellustgarten.
Blood testing with LifeExtension.com: https://www.anrdoezrs.net/click-101614996-15750394
At-Home Metabolomics: https://www.iollo.com?ref=michael-lustgarten.
Use Code: CONQUERAGING At Checkout.
Clearly Filtered Water Filter: https://get.aspr.app/SHoPY
Epigenetic, Telomere Testing: https://trudiagnostic.com/?irclickid=U-s3Ii2r7xyIU-LSYLyQdQ6…M0&irgwc=1
This paper formalizes biological intelligence as search efficiency in multi-scale problem spaces, aiming to resolve epistemic deadlocks in the basal “cognition wars” unfolding in the Diverse Intelligence research program. It extends classical work on symbolic problem-solving to define a novel problem space lexicon and search efficiency metric. Construed as an operationalization of intelligence, this metric is the decimal logarithm of the ratio between the cost of a random walk and that of a biological agent. Thus, the search efficiency measures how many orders of magnitude of dissipative work an agentic policy saves relative to a maximal-entropy search strategy. Empirical models for amoeboid chemotaxis and barium-induced planarian head regeneration show that, under conservative (i.e.
Cancer and Alzheimer’s are two of the most common chronic diseases associated with aging. For years, doctors have known about a curious aspect of these two conditions: people who survive cancers are significantly less likely to develop Alzheimer’s. While this link has been observed in the data for some time, the biological reasons for it have remained a mystery. Now, a new study published in the journal Cell has discovered a possible explanation.
In the Alzheimer’s brain, abnormal levels of a naturally occurring protein called amyloid-beta clump together to form plaques. The plaques disrupt communication between brain cells, eventually leading to cognitive decline and memory loss. Current medicines struggle to remove these clumps, but this new research suggests that cancer might be sending in a biological cleanup crew.
To see whether and how cancer provides this protection, researchers at the Huazhong University of Science and Technology in China used advanced mouse models of Alzheimer’s disease. They transplanted three types of tumors (lung, colon and prostate cancer) into the mice and found that the amyloid plaques in their brains shrank significantly.
The musk blueprint: navigating the supersonic tsunami to hyperabundance when exponential curves multiply: understanding the triple acceleration.
On January 22, 2026, Elon Musk sat down with BlackRock CEO Larry Fink at the World Economic Forum in Davos and delivered what may be the most important articulation of humanity’s near-term trajectory since the invention of the internet.
Not because Musk said anything fundamentally new—his companies have been demonstrating this reality for years—but because he connected the dots in a way that makes the path to hyperabundance undeniable.
[Watch Elon Musk’s full WEF interview]
This is not visionary speculation.
This is engineering analysis from someone building the physical infrastructure of abundance in real-time.
A former professor at the University of California, Los Angeles, Horvath is now principal investigator of the U.K. research arm of Altos Labs, a longevity biotech company that says it is developing therapies that could reverse age-related diseases and disabilities.
Having precise and meaningful ways to measure aging could make it possible for drug developers like Altos Labs to test longevity treatments in people, Horvath says: “It’s a quintessential tool to find interventions for rejuvenation.”
As part of TIME’s series interviewing longevity leaders and influencers, we spoke to Horvath about his pioneering invention and what he thinks might be possible for human life extension.
